skip-to-main

Spikevax JN.1 50 micrograms dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine

Spikevax JN.1 is indicated for active immunisation to prevent COVID 19 caused by SARS-CoV-2 in individuals 12 years of age and older.

Patient Information Leaflet

Summary of Product Characteristics

Spikevax XBB.1.5 0.1 mg/mL dispersion for injection

Spikevax XBB.1.5 50 micrograms dispersion for injection

Spikevax XBB.1.5 50 micrograms dispersion for injection in pre-filled syringe

Spikevax XBB.1.5 is indicated for active immunisation to prevent COVID‑19 caused by SARS-CoV-2 in individuals 12 years of age and older.

Patient Information Leaflet

Summary of Product Characteristics

Spikevax bivalent Original/Omicron BA.4-5 (50 micrograms/50 micrograms)/mL dispersion for injection

Emergency Use Authorization (EUA) has been granted in Qatar for Spikevax bivalent Original/Omicron BA.4-5 for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.

Patient Information Leaflet

Summary of Product Characteristics

Spikevax bivalent Original/Omicron BA.1 (50 micrograms/50 micrograms)/mL dispersion for injection

Emergency Use Authorization (EUA) has been granted in Qatar for Spikevax bivalent Original/Omicron BA.1 for active immunisation to prevent COVID‑19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID‑19.

Patient Information Leaflet

Summary of Product Characteristics

Spikevax (Previously COVID-19 Vaccine Moderna)

Emergency Use Authorization has been granted in Qatar for Spikevax (COVID-19 Vaccine Moderna) to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.

Patient Information Leaflet

Summary of Product Characteristics

Tools

Temperature Excursion Tool

See what to do with vials of the Moderna COVID-19 Vaccine that may have experienced a temperature excursion prior to administering.

Contact Moderna

How can we help you?

Report a Side Effect: Adverse Event Intake Portal
Email Us: WeCare@modernatx.com
Call Us: 00800101103 Sunday - Thursday 9:00 AM to 5:00 PM AST (closed holidays)

    © 2024 Moderna, Inc.

    QA-COV-2100001 09/2024